e-Article
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
Document Type
article
Author
Jagannathan, Prasanna; Chew, Kara W; Giganti, Mark J; Hughes, Michael D; Moser, Carlee; Main, Mark J; Monk, Phillip D; Javan, Arzhang Cyrus; Li, Jonathan Z; Fletcher, Courtney V; McCarthy, Caitlyn; Wohl, David A; Daar, Eric S; Eron, Joseph J; Currier, Judith S; Singh, Upinder; Smith, Davey M; Fischer, William; Team, ACTIV-2 A5401 Study; Chew, Kara; Smith, David; Daar, Eric; Wohl, David; Currier, Judith; Eron, Joseph; Hughes, Michael; Giganti, Mark; Ritz, Justin; Hosey, Lara; Roa, Jhoanna; Patel, Nilam; Colsh, Kelly; Rwakazina, Irene; Beck, Justine; Sieg, Scott; Li, Jonathan; Fletcher, Courtney; Evering, Teresa; Ignacio, Rachel Bender; Cardoso, Sandra; Corado, Katya; Jilg, Nikolaus; Perelson, Alan; Pillay, Sandy; Riviere, Cynthia; Taiwo, Babafemi; Gottesman, Joan; Newell, Matthew; Pedersen, Susan; Dragavon, Joan; Jennings, Cheryl; Greenfelder, Brian; Murtaugh, William; Kosmyna, Jan; Gapara, Morgan; Shahkolahi, Akbar; Pierone, Gerald; Elliott, Juliana; Jacobson, Jeffrey; Hojat, Leila; Pasternak, Julie; Berardi, Jonathan; Arar, Celine; Bukhman, Yevgeniy; Jain, Manish; Bukhman, Eugene; Shaik, Sadia; Hatlen, Timothy; Dooley, Kelly; Becker, Becky; Wilkins, Adaliah; Pérez, Jose; Roman, Eloy; Fernández, Heriberto; Hoover, Keila; Renfroe, James; Weldon, Mauney; Bougher, Genei; Malvestutto, Carlos; Harber, Heather; Cicarella, Robyn; Neytman, Gene; Herman, Jack; Herman, Craig; Aziz, Mariam; Swiatek, Joan; Pathak, Divya; Choudhary, Madhu; Sullivano, Jennifer; Osiyemi, Olayemi; Izquierdo, Myriam; Torna, Odelsey; Khodabakhshian, Aleen; Fortier, Samantha
Source
Subject
Language
Abstract
BackgroundWith the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains a critical need.MethodsSafety, clinical and antiviral efficacy of inhaled interferon-β1a (SNG001) were evaluated in a phase II randomized controlled trial on the ACTIV-2/A5401 platform (ClinicalTrials.govNCT04518410). Adult outpatients with confirmed SARS-CoV-2 infection within 10 days of symptom onset were randomized and initiated either orally inhaled nebulized SNG001 given once daily for 14 days (n = 110) or blinded pooled placebo (n = 110) between February 10 and August 18, 2021.FindingsThe proportion of participants reporting premature treatment discontinuation was 9% among SNG001 and 13% among placebo participants. There were no differences between participants who received SNG001 or placebo in the primary outcomes of treatment emergent Grade 3 or higher adverse events (3.6% and 8.2%, respectively), time to symptom improvement (median 13 and 9 days, respectively), or proportion with unquantifiable nasopharyngeal SARS-CoV-2 RNA at days 3 (28% [26/93] vs. 39% [37/94], respectively), 7 (65% [60/93] vs. 66% [62/94]) and 14 (91% [86/95] vs. 91% [83/81]). There were fewer hospitalizations with SNG001 (n = 1; 1%) compared with placebo (n = 7; 6%), representing an 86% relative risk reduction (p = 0.07). There were no deaths in either arm.InterpretationIn this trial, SNG001 was safe and associated with a non-statistically significant decrease in hospitalization for COVID-19 pneumonia.FundingThe ACTIV-2 platform study is funded by the NIH. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.